Pharmacotherapy for refractory schizophrenia patients

References

• Essock SM, Hargreaves WA, Dohm FA, Goethe J, Carver L, Hipshman L Clozapine eligibility among sate hospital patients. Schiz. Bull 22, 15–25 (1996).
   PubMed Web of Science ®Google Scholar
• Hon i A, Tsunashima K, Takekawa K, Ishihara I, Terada T, Uno M. Criteria for refractory schizophrenia. Acta PTchiat. Scant 99, 141–147 (1999).
   PubMedGoogle Scholar
• •Attempts to define and classify resistance.
   Google Scholar
• Kane J, Honigfeld G, Singer J, Meltzer H and the Clozaril Collaborative Study Group. Iozapine for the treatment-resistant schizophrenic: a double-blind comparison vs. chlorpromazine. Arch. Gen. Psych. 45, 789–796 (1988).
   Google Scholar
• Brenner HD, Dencker SJ, Goldstein MJ et al. Defining treatment refractoriness in schizophrenia. Schiz. Buff. 16, 551–560 (1990).
   PubMed Web of Science ®Google Scholar
• •Attempts to define and classify resistance.
   Google Scholar
• Meltzer FLY Commentary: defining treatment refractoriness in schizophrenia. Schiz. Bull. 16, 563–565 (1990).
   PubMedGoogle Scholar
• Addington J, Addington D, Matricka- Tyndale E. Cognitive functioning and negative symptoms in schizophrenia. Schiz. Res. 5, 123–134 (1991).
   Google Scholar
• Green ME What are the functional consequences of neurocognitive deficits in schizophrenia? Am. J Psychcol 153, 312–330 (1996).
   Google Scholar
• Gunter. Do Nurses have the power to cause, prevent and cure 'Social BreakDown's syndrome?' J Gerontol NUTS. 6, 650–651 (1980).
   Google Scholar
• Paul GL, Redfield JP, Lentz RJ. The in- patient Scale of Minimal Functioning: a revision of the Social BreakDown's syndrome Gradient Index. J Consult. Clin. PTchol. 44, 1021–1022 (1976).
   Google Scholar
• Ungvari GS, Hantz PM. Social BreakDown's syndrome in the elderly. Case studies and management. Compr. Psych/at. 32, 440 444 (1991).
   Google Scholar
• Bilder RiVI, Wu H, Chakos MH, Bogerts B, Pollack S, Aronowitz J et al Cerebral morphometry and clozapine treatment in schizophrenia. J Clin. Psych. 55(Suppl. B), 53–56 (1994).
   Google Scholar
• Stern RG, Kahn RS, Davidson M. Predictors of response to neuroleptic treatment in schizophrenia. Psych. Clin. N Arn. 16, 313–338 (1993).
   Google Scholar
• Ota P, Maeshiro H, Ishido H, Shimizu Y, Uchida R, Toyoshima R Treatment-resistant chronic psychopathology and CT scans in schizophrenia. Acta. Psych. Scan. 75, 415–427 (1987).
   PubMed Web of Science ®Google Scholar
• Faraone SV, Green AT, Brown W Yin P, Tsuang MT. Neuroleptic dose reduction in persistently Psychotic. Hosp. Corn. Psych. 40, 1193–1195 (1989).
   PubMedGoogle Scholar
• Hirsch SR, Barnes TRE. Clinical use of high dose neuroleptics. BE J Psych. 164, 94–96 (1994).
   PubMed Web of Science ®Google Scholar
• •Provides the effects and side effects of high-doses and the precautions to be taken when a high-dose is instituted.
   Google Scholar
• Koshino Y. Algorithm for treatment refractory schizophrenia. Psych. Clin.Neurosci 53(Suppl), S9—S13 (1999).
   Google Scholar
• •Attempts to define and classify resistance.
   Google Scholar
• Van Putten T, Marshall BD, Lieberman R, Mintz J, Keuhnel TG, Bowen L etal Systematic dosage reduction in treatment resistant schizophrenic patients. PTchophalmacol. Bull 29, 315–320 (1993).
   PubMedGoogle Scholar
• Ananth JV. Exacerbation of psychopathology during treatment: etiology. Comp. Psych. 14, 563–568 (1973).
   PubMedGoogle Scholar
• Ananth JV, Jain RC. Benztropine psychosis. Can. Psych. Assoc. J 18, 409–414 (1973).
   PubMedGoogle Scholar
• Ananth J, Djenderedjian A, Mendoza R, Cheung D. Acute and chronic lithium toxicity: case reports and a review. Lithium 3,139–145 (1992).
   Google Scholar
• Van Putten T. The many faces of akathisia. Comp. Psych. 16, 111–121 (1975).
   Google Scholar
• Lieberman J, Jody D, Geisler S, Alvir J et al Time course and biologic correlates of treatment response in first-episode schizophrenia. Arch. Gen. Psych. 50, 369–376 (1993).
   PubMed Web of Science ®Google Scholar
• Van Kammen DP, Schooler N. Arebiochemical markers for treatment-resistant schizophrenia state dependent or traits? Clin. Neuropharmacol 13, 516–528 (1990).
   Google Scholar
• Fukuzako H, Takeuchi K, Ueyama K etal. 31P magnetic resonance spectroscopy of the medial temporal lobe of schizophrenic patients with neuroleptic-resistant marked positive symptoms. Eur. Arch. Psychiatry Clin. Neurosci. 244, 236–240 (1994).
   Google Scholar
• Keshavan MS, Bagwell WW Haas GL, Sweeney JA, Schooler N, Pettegrew JW. Changes in caudate volume with neuroleptic treatment. Lancet344, 1434 (1994).
   PubMed Web of Science ®Google Scholar
• Pettegrew JA, Keshavan JS, Panchalingam K et al Alterations in brain high energy phosphate and membrane phospholipid metabolism in first episode, drug naive schizophrenics. A:Th. Gen Bich. 48, 563–568 (1991).
   Google Scholar
• Stanely JA, Williamson PC, Drost DJ et al An in vivo study of the prefrontal cortex schizophrenic patients at different stages of the illness via phosphorus magnetic resonance spectroscopy. Arch Gen Psych. 52,399–406 (1995).
   PubMedGoogle Scholar
• Sheitman BB, Murray MG, Snyder JA, et al IQ scores of treatment-resistant schizophrenia patients before and after the onset of the illness. Schiz. Res 46, 203–207 (2000).
   PubMed Web of Science ®Google Scholar
• Breakey WR, Goodell H, Lorenz PC. Hallucinogenic drugs as precipitant of schizophrenia. 4chol. Med. 11,499-500 (1974).
   Google Scholar
• Linszen DH, Dingemans PM, Lenior ME. Cannabis abuse and the course of recent onset of schizophrenic disorders. Arch. Gen. Psych. 51, 273–279 (1994).
   Google Scholar
• Metzer FLY Dimensions of outcome with clozapine. BE J Psych. 160\(Suppl. 17), 46–53 (1992).
   Google Scholar
• Noordsey, DL, Drajke RE, Teague GB, Osher SC, Beaudett MS, Paskus TS. Subjective experiences related to alcohol use among schizophrenics. J. Nerv. Ment. Dis. 179, 410–414 (1991).
   Google Scholar
• Soyka M. Substance misuse, psychiatric disorder and violent and disturbed behavior. BE J. Psych. 176, 345–350 (2000).
   PubMed Web of Science ®Google Scholar
• Miller NS, Gold MS, Mailer JC. Violent behaviors associated with cocaine use: possible pharmacological mechanisms. Int. J. Addict. 26, 1077–1088 (1991).
   Google Scholar
• Mulvey EP. Assessing the evidence of a link between mental illness and violence. Hosp. Corn. Psych. 45, 663–668 (1994).
   PubMedGoogle Scholar
• Negrette JC, Knapp WP, Douglas DE, Smith WB. Cannabis affects the severity of schizophrenic symptoms: results of a clinical survey. Psychol. Med. 16, 515–520 (1986).
   PubMedGoogle Scholar
• Smith J, Hucker S. Schizophrenia and substance abuse. BE J. Psych. 165, 13–21 (1994).
   PubMed Web of Science ®Google Scholar
• Soyka, M. Substance abuse and dependency as a risk factor for delinquency and violent behavior in schizophrenic patients — how strong is the evidence? J. Clin. Forensic Med. 1, 3–7 (1994)
   PubMedGoogle Scholar
• Buckley P, Thompson P, Way L, Seltzer HY. Substance abuse among patients with treatment-resistant schizophrenia: characteristics and implications for clozapine therapy. Am. J. Psych. 151, 385–389 (1994).
   PubMed Web of Science ®Google Scholar
• Olney JW, Faber NB. Glutamic receptor dysfunction and schizophrenia. Arch. Gen Psych. 52, 998–1007 (1995).
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Safferman AZ, Pollack S et al effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome. Am J. Psych. 151, 1744–1752 (1994).
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Alvir JM, Koreen A etal Psychobiologic correlates of treatment response in schizophrenia. Neuropsychopharmacology14\(Suppl. 3), S13—S21 (1996).
   Google Scholar
• Beerport q, Lipska BK, Weinberger DR Neurobiology of treatment-resistant schizophrenia: new insights and new models. Eur. Neumpsychopharmacol 6\(Suppl. 2), 27–34, 1996.
   Google Scholar
• •Attempts to define and classify resistance.
   Google Scholar
• Feinberg I. Schizophrenia: caused by a faultin programmed synaptic elimination during adolescence? J. Psych. Res. 17, 319–334 (1982).
   Google Scholar
• Lewis DA. Development of prefrontal cortex during adolescence: insights into vulnerable neural circuits in schizophrenia. Neuropsychophannacology 16, 358–398 (1997).
   Web of Science ®Google Scholar
• Alvir JM, Woemer MG, Gunduz H, Degreef G, Lieberman JA. Obstetric complications predict treatment-response in first episode schizophrenia. Psychol. Med. 29(3), 21–27 (1999).
   Google Scholar
• Marx CE, Vance BJ, Jarskog LF, Chescheir NC, Gilmore JH. Nerve growth factor, brain-derived neurotrophic factor and neurotrophin-3 levels in human amniotic fluid. Aimj Obstet. Gynecol 181(5 pt. 1), 1225–1230 (1999).
   Google Scholar
• Murray RiVI, O'Callaghan E, Castle DJ, Lewis SW A neurodevelopmental approach to the classification of schizophrenia. Schizophr Bull 18,319–332 (1992).
   PubMedGoogle Scholar
• Kinon BJ, Kane JM, Chakos M, Munne R Possible predictors of neuroleptic-resistant schizophrenic relapse: Influence of negative symptoms and acute extrapyramidal side effects. Bychopharmacol Bull 29, 365–369, (1993).
   PubMedGoogle Scholar
• Van Putten T, Marder SR, Mintz J. A controlled dose comparison of haloperidol in newly admitted schizophrenic patients. Arch. Gen. Psycht. 47, 754–758 (1990).
   Google Scholar
• Coppens HJ, Sloof CJ, Paans AMJ, Weigman T, Vaalburg NO," KorfJ. High central D2 dopamine receptor occupancy as assessed with positron emission tomography in medicated but therapy resistant schizophrenic patients. Biol. Psych 29, 629-634(1991).
   Google Scholar
• Potkin SG, Jin Y, Gulasekaran B eta]. Schizophrenic syndromes and clozapine response in treatment-resistant schizophrenia. Psych. Res. 77, 21–28 (1994).
   Google Scholar
• Rodriguez VM, Catalina ML, Garcia- Noblejas JA, Cuesta P. Schizophrenic syndromes and clozapine response in treatment-resistant schizophrenia. Psychiatry Res. 16, 77, 21–28 (1998).
   Google Scholar
• Lahdelma L, Ahokas A, Andersson LC, Huttenen M, Sarna S, Koskimies S. Association between HLA-A1 allele and schizophrenia genes in patients refractory to conventional neuroleptics but responsive to clozapine medication. Tissue Antigens 51, 200–203 (1998).
   PubMedGoogle Scholar
• Breier A, Hamilton SH. Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia. Biol. Psych. 45, 403–411 (1999).
   PubMed Web of Science ®Google Scholar
• Clozapine Study Group. The safety and efficacy of clozapine in severe treatment resistant schizophrenic patients in the UK. Br. PTch. 163, 150–154(1993).
   PubMed Web of Science ®Google Scholar
• Jalenques I, Coudert AJ. A new therapeutic approach to drug-resistant schizophrenic patients: clozapine. Long-term prospective study in 16 patients. Acta Psych. Belg. 92, 323–338 (1992).
   Google Scholar
• Kane J M, Marder SR, Schooler N, Wirshing WC, Umblight D, Baker RW Olanzapine and haloperidol in moderately refractory schizophrenia. Arch Gen. Psych. 58, 965–972 (2001).
   PubMedGoogle Scholar
• Owen RR, Beake BJ, Marby D, Dessain EC, Cole JO. Response to clozapine in chronic psychotic patients. Psychopharmacol. Bull. 25, 253–256 (1989).
   Google Scholar
• Schooler N, Kane JM, Marder S, Baker R, Safferman A, Wirshing W Efficacy of clozapine vs. haloperidol in a long-term clinical trial: preliminary findings. Schiz. Res. 15, 165 (1995).
   Google Scholar
• Melzter FIY. Treatment of the neuroleptic- nonresponsive schizophrenic patient. Schiz. Bull 18 (3), 515–542 (1992).
   PubMedGoogle Scholar
• Umbricht DS, Lieberman JA, Kane JM. The clinical efficacy of clozapine in the treatment of schizophrenia: a Gaussier mixture analysis of 1056 cases and controls. Biol. Psych. 30, 887–903 (1995)
   Google Scholar
• Rosenheck, R, Cramer J, Xu Wet al A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. N Engl. I Med. 337, 808–815 (1997).
   Google Scholar
• Chakos M, Lieberman J, Hoffman E, Bradford D, Sheitman B. Effectiveness of second generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am. .1. Psych. 158, 518–526 (2001).
   Google Scholar
• •Review of polypharmacology. Critically reviews the use of various agents as augmentation or supplemental therapy in schizophrenia.
   Google Scholar
• Baldacchino AM, Stubbs JH, Nevinson- Andrews D. The use of olanzapine in noncompliant or treatment resistant clozapine populations in hospital. Phatm. 260, 207–209 (1998).
   Google Scholar
• Dossenbach MRK, Beuzen JN, Avnon M et al The effectiveness of olanzapine in treatment-refractory schizophrenia when patients are nonresponsive to or unable to tolerate clozapine. Clin. Ther. 22, 1021–1034 (2000).
   PubMed Web of Science ®Google Scholar
• Ohaeri JU. Naturalistic study of olanzapine in treatment resistant schizophrenia and acute mania depression and obsessional disorder. East Ab: Med. J77, 86–92 (2000).
   Google Scholar
• Conley RR, Tamminga CA, Barton JJ eta]. Olanzapine vs. chlorpromazine in treatment-resistant schizophrenia. Am. Psych. 155, 914–920 (1998).
   Google Scholar
• Breier A, Buchanan RW, Irish D, Carpenter WT Jr. Clozapine treatment of outpatients with schizophrenia: outcome and long-term response patterns. Hasp. Cam. Psych. 44,1145-1149 (1993).
   Google Scholar
• Mountjoy CQ, Balcia chino AM, Stubbs JH. British experience with high dose olanzapine for treatment of refractory schizophrenia. Am Psych 156, 158–159 (1999).
   Google Scholar
• Weiss EL, Longhurst JG, Bowers MB Jr., Mazure CM. Olanzapine for treatment-refractory psychosis in patients responsive to but intolerant of clozapine. I Clin. fiychopharmacol 19, 378–380 (1999).
   Google Scholar
• Conley RR, Meltzer I-if. Adverse events related to olanzapine. I Clin. Psych. 61\(Suppl. 8), 26–29, 2000.
   Google Scholar
• Klieser E, Lehman E, Kinzler E, Wurthmann C, Heinrich K. Randomized, double-blind, controlled trial of risperidone versus clozapine in patients with chronic schizophrenia. Clin. Psychopharmacol. 15\(Suppl. 1), 45S-51S (1995).
   Google Scholar
• Bondolfi G, Dufour H, Patris M etal Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. Am. Psych. 155, 499–504 (1998).
   Google Scholar
• Azorin JM, Speigel R, Remington G eta]. A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia. Arn.1 Psych. 58, 1305–1313 (2001).
   Google Scholar
• •Explores the usefulness of antipsychotic drug combinations.
   Google Scholar
• Daniel, DG, Goldberg TE, Weinberger DR etal Different side effect profiles of risperidone and clozapine in 20 outpatients with schizophrenia or schizoaffective disorder: a pilot study. Am. I Psych. 153, 417–419 (1996).
   Google Scholar
• Lindenmayer JP, Iskander A, Park M, Apergi FS, Smith R, Allen D. Clinical and neurocognitive effects of clozapine and risperidone in treatment refractory schizophrenic patients: a prospective study. I Clin. Psych. 59, 521–527 (1998).
   Google Scholar
• Wirshing DA, Barringer D, Marshall D Jr., Green MF, Mintz J, Marder SR Risperidone in Treatment Refractory Schizophrenia. Am. I Psych. 156, 1374–1379 (1999).
   Google Scholar
• Emsley RA, Raniwalla J, Bailey PJ, Jones AM. A comparison of the effects of quetiapine and haloperidol in schizophrenic patients with a history of and a demonstrated partial repose to conventional antipsychotic treatment. Int. Clin. PTchopharmacol 15, 121–131 (2000).
   PubMed Web of Science ®Google Scholar
• Goldstein J, Buckley P Comparison of the effects of quetiapine and haloperidol in a cohort of patients with treatment-resistant schizophrenia. Int. Clin. Psychopharmacol 15(3), 121–131 (2000).
   Google Scholar
• Baird JW. The utility of quetiapine in patients with a history of poor response to previous treatment. I Clin. Psych. 60\(Suppl. 23), 15–16 (1999).
   Google Scholar
• Reznik I, Benatov R, Sirota P. Long-term efficacy and tolerability of treatment refractory schizophrenia: a case study. I Clin. Psych. 60\(Suppl. 23), 16–17 (1999).
   Google Scholar
• Shaw M, Brown R Quetiapine in psychosocial rehabilitation of a patient with chronic schizophrenia. I Clin. Psych. 60\(Suppl. 23), 17 (1999).
   Google Scholar
• Szigethy E„ Brent S, Findling RL. Quetiapine in refractory schizophrenia. JAm. Acad. Child Adolesc. Psych. 37, 1127–1128 (1998).
   PubMedGoogle Scholar
• Takhar J. Pirnozide augmentation in a patient with drug-resistant psychosis previously treated with olanzapine. I Psych. Neurosci. 24, 248–249 (1999).
   PubMedGoogle Scholar
• Thompson C. The use of high dose antipsychotic medication. BE I Psych. 164, 448–458 (1994).
   PubMedGoogle Scholar
• •Provides the effects and side effects of high-doses and the precautions to be taken when a high-dose is instituted.
   Google Scholar
• Solano OA, Sadow T, Ananth J. Rapid tranquilization: a re-evaluation. Neuropsychobiology22, 90–96 (1989).
   PubMedGoogle Scholar
• Bollini P, Andreani A, Clomobo F, Bellantuono C, Beretta P, Arduni A. High dose neuroleptics: uncontrolled clinical practice confirms controlled clinical trials. BE I Psych. 144, 25–27 (1984).
   PubMed Web of Science ®Google Scholar
• •Provides the effects and side effects of high-doses and the precautions to be taken when a high-dose is instituted.
   Google Scholar
• Aubree JC, Lader MH. High and very high dosage antipsychotics: a critical review. Clin. Psych. 41, 341–350 (1980).
   Google Scholar
• •Provides the effects and side effects of high-doses and the precautions to be taken when a high-dose is instituted.
   Google Scholar
• Baldessarini RJ, Cohen BM, Teicher MH. Sficance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Arch. Cen Bich. 45,79–91(1988).
   Google Scholar
• Bjomdal N, Bjerre M, Gerlach J eta]. High dosage haloperidol therapy in chronic schizophrenic patients: a double-blind study of clinical response, side effects, serum haloperidol and serum prolactin. PTchopharmacology67, 17–23 (1980).
   PubMedGoogle Scholar
• Dencker SJ, Johansson R, Lundin L, Malin U. High doses of fluphenazine enanthate in schizophrenia: a controlled study. Acta Psych. Scan. 57, 405–414 (1978).
   PubMedGoogle Scholar
• Itil T, Keskiner A, Heinemann L, Han T, Gannon P, Hsu W Treatment of resistant schizophrenics with extreme high dosage fluphenazine hydrochloride. Psychosomatics 11,456–463 (1970).
   PubMed Web of Science ®Google Scholar
• Kane JM. The use of higher-dose antipsychotic medication. BE I Psychiatry 164, 431–432 (1994).
   PubMed Web of Science ®Google Scholar
• McClelland HA, Farquharson RG, Leyburn R Furness JA, Schiff AA. Very high dose fluphenazine decanoate: a controlled trial in chronic schizophrenia. Arch. Gen Psych. 33, 1435–1439 (1976).
   Google Scholar
• McCreadie RG, Flanagan WL, McKnight J, Jorgensen A. High dose flupenthixol decanoate in chronic schizophrenia. Br]. Psychiatry 135, 175–179, 1979.
   PubMed Web of Science ®Google Scholar
• Prien RF, Cole JO. High dose of chlorpromazine in chronic schizophrenia. Arch. Gen. Psych. 18, 482–495 (1968).
   PubMed Web of Science ®Google Scholar
• Quitkin F, Rifkin A, Klein D. Very high dosage vs. standard dosage fluphenazine in schizophrenia: a double-blind study of nonchronic treatment-refractory patients. Arch. Gen. Psych. 32,1276-1281 (1975).
   Google Scholar
• Rifkin A, Doddi S, Karajgi B, Borenstein M, Wachspress M. Dosage of haloperidol for schizophrenia. Arch. Gen. Psych. 48, 166–170 (1991).
   PubMed Web of Science ®Google Scholar
• Remington G, Pollack B, Voineskos G, Reed K, Coulter K. Acutely psychotic patients receiving high-dose haloperidol therapy. I Clin. PTchoparmacol 13, 41–45 (1993).
   Google Scholar
• Volavka J, Cooper TB, Czobor P eta]. High dose treatment with haloperidol: the effect of dose reduction. 20, 252–256 (2000).
   Google Scholar
• Kinon BJ, Kane JM, Johns C eta] Treatment of neuroleptic resistant schizophrenic relapse. Psychopharmacol Bull 29, 309–314 (1993).
   PubMedGoogle Scholar
• Fouks L Originalite et specificite de al fluphenazine. In: Proceedings of the Fifth Congess of Neuropsychopharmacology Washington DC 1966 Amsterdam, Excerpta Medica Foundation, International Congress Series no.192, 1128–1134, (1967).
   Google Scholar
• Gayral L, Lambet P. La dicholorohydrate de fluphenazine:Etude des doses eleves et des traiment de longue duree. In: Proceedings of the Fifth International Congress of NeuropsychopharmacologyWashington DC 1966. Amsterdam Excerpta Medica Foundation International Congress Series 129, 1128-1134(1967).
   Google Scholar
• Levinson DF, Simpson GM, Singh H eta]. Fluphenazine dose, clinical response and extrapyramidal symptoms during acute treatment. Arch. Gen. Psych. 47, 761–768 (1990).
   Google Scholar
• Polvan N, Yagcioglu V, Itil M. High and very high dose fluphenazine in the treatment of chronic psychosis. In: The Resent Status Of Porhotropic Drugs, Pharmacological Ancl Clinical Aspects: Proceedings Of The Sixth Internationale Neuropsychopharmacologicum, Tarragona Spain, April 1968. Cerletti A, Bore FJ (Eds). Amsterdam Excerpta Medica Foundation, International Congress series 180, 495–497 (1969).
   Google Scholar
• Rifkin A, Quitkin F, Carrillo C, Klein DE Very high dosage fluphenazine for nonrefractory patients. Arch. Gen. Psych. 25, 398–403 (1971).
   PubMedGoogle Scholar
• Reich J. Use of high-dose olanzapine in refractory psychosis. Am. I Psychiatry 156, 661 (1999).
   PubMedGoogle Scholar
• Alao AO, Armenta WA, Yolles JC. High-dose olanzapine therapy in schizophrenia. Ann. Pharmacother. 33, 1228 (1999).
   PubMed Web of Science ®Google Scholar
• Dursun SM, Gardner DM, Bird DC, Flinn J. Olanzapine for patients with resistant schizophrenia: a naturalistic outcome study. Can. I Psych. 44, 701–704 (1999).
   PubMed Web of Science ®Google Scholar
• Fanous A, Lindenmayer JP. Schizophrenia and schizoaffective disorder treated with high doses of olanzapine. I Clin. Fiychopharmacol 19, 275–276 (1999).
   PubMed Web of Science ®Google Scholar
• Heimann SW High-dose olanzapine in an adolescent. I Am. Acad. Child Adolesc. Psych. 38, 496–498 (1999).
   Google Scholar
• Launer MA. High dose olanzapine in treatment resistant schizophrenia. Schizophrenia Res. 29, 149–150 (1998).
   Web of Science ®Google Scholar
• Volavka J, Czobor P Sheitman B eta] Clozapine, olanzapine, risperidone and haloperidol in patients with chronic schizophrenia and schizoaffective disorder. Am. I Psych. 159, 255–262 (2002).
   PubMed Web of Science ®Google Scholar
• •Provides the effects and side effects of high-doses and the precautions to be taken when a high-dose is instituted.
   Google Scholar
• Shad ZA, Treatment refractory schizophrenia: how should we proceed? Psychiatric Quarterly 69(4), 263–281 (1998).
   Google Scholar
• Sheitman BB, Lindgren JC, Early J, Sved M. High-dose olanzapine for treatment-refractory schizophrenia. Am. I Psychiatry 154, 1626 (1997).
   PubMed Web of Science ®Google Scholar
• Lindenmayer JP, Volavka J, Lieberman J, Sheitman B, Citrome L, Chakos M. Olanzapine for schizophrenia refractory to typical and atypical antipsychotics: an open-label, prospective trial. I Clin. Fiychopharmacol 21(4), 448–453 (2001).
   PubMed Web of Science ®Google Scholar
• Small JG, Hirsch SR, Arvanitis LA, Miller BG, Link CGG. Quetiapine in patients with schizophrenia. A high and low dose double-blind comparison with placebo. Arch. Gen. Psych. 54, 549–557 (1997).
   Google Scholar
• Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am. Psych. 151, 825–835 (1994).
   Google Scholar
• Little KY, Gay TL, Vore M. Predictors of response to high dose antipsychotics in chronic schizophrenics. Psych. Res. 30, 1–9 (1989).
   Google Scholar
• Gardos G, Cole JO, Orzack MH. The importance of dosage in antipsychotic drug administration, a review of dose-response studies. PTchopharmacologia 29, 221–230 (1973).
   Google Scholar
• Goldney RD, Spence ND, Bowes JA. The safe use of high dose neuroleptics in a psychiatric intensive care unit. Aust. NZ Psych. 20, 370–375 (1986).
   Google Scholar
• Simpson GM, Davis J, Jefferson JW Sudden deaths in psychiatric patients: the role of neuroleptic drugs. American Psychiatric Association task force report. 27, (1987).
   Google Scholar
• Zimbroff DL, Kane JM, Tarruninga CA et al and the Sertindole Study Group. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Am. I Psychiatry 154, 782–791 (1997).
   Google Scholar
• Tran PV, Delva MA, Tollefson GD etal. Oral olanzapine vs. oral haloperidol in the maintenance treatment of schizophrenia and related psychoses. BE I Psych. 172, 499–505 (1998).
   Google Scholar
• Canales PL, Olsen J, Miller AL Crimson ML. Role of antipsychotic polypharmacy in the treatment of schizophrenia. CNS Drugs 12, 179–188 (1999).
   Google Scholar
• •Review of polypharrnacology. Critically reviews the use of various agents as augmentation or supplemental therapy in schizophrenia.
   Google Scholar
• Davis JM, Casper R Antipsychotic drugs: clinical pharmacology and therapeutic use. Drugs 14, 260–282(1977).
   PubMed Web of Science ®Google Scholar
• Raskin S, Durst R, Katz G, Zislin J. Olanzapine and sulpiride combination/ augmentation in patients with treatment resistant schizophrenia. I Clin. Psychopharmacol 20, 500–503 (2000).
   Google Scholar
• Warner JP Gledhill JA, Wakeling A. The use of risperidone in the treatment of resistant schizophrenia: two case reports. Int. I Clin. Fiychopharmacol 11,65–66 (1996).
   PubMedGoogle Scholar
• Henderson DC, Goff DC. Risperidone as an adjunct to clozapine therapy in chronic schizophrenia. J Clin. Psych. 57,395–397 (1996).
   Google Scholar
• Lerner V, Chudakova B, Kravets S, Polykova I. Combined use of risperidone and olanzapine in the treatment of patients with resistant schizophrenia: a preliminary report. Clin. Neumpharmacol 23,284–286 (2000).
   PubMed Web of Science ®Google Scholar
• Morera AL, Barriero P, Cano-Munoz JL. Risperidone and clozapine combination for the treatment of refractory schizophrenia. Acta nych. Scam 99,305–307 (1999).
   Google Scholar
• Raskin S, Katz G, Zislin Z, Knobler HY, Durst R Clozapine and risperidone: combination/augmentation treatment of refractory schizophrenia, a preliminary observation. Acta Psych. Sam/. 101,334–336 (2000).
   PubMed Web of Science ®Google Scholar
• McCarthy RI-I, Terkelsen KG. Risperidone augmentation of clozapine. Pharmacopsychiarry28, 61–63 (1995).
   Google Scholar
• Bather NM, Kaup BA. Combining risperidone with standard neuroleptics for refractory schizophrenic patients. Am. J By& 153,137 (1996).
   Google Scholar
• •Explores the usefulness of antipsychotic drug combinations.
   Google Scholar
• Still DJ, Dorson PG, Crismon ML, Pousson C. Effects of switching in-patients with treatment resistance from clozapine to risperidone. Psychiatric Services 47, 1382–1384 (1996).
   PubMed Web of Science ®Google Scholar
• Flynn SW, MacEwan GNO," Altman S et al An open comparison of dozapine and risperidone in treatment resistant schizophrenia. Pharmacopsychiatiy31, 25–29 (1998).
   PubMed Web of Science ®Google Scholar
• Finn MHP, Nodolski F, Guy W Gross M. Clinical, psychological and myoneural changes in psychotic patients under oral Serpasil medication. J. Nerv. Mental Dis. 122,458–462, (1958).
   Google Scholar
• Hollister LE, Krieger GE, Kringel A, Roberts RH. Treatment of chronic schizophrenic reactions with reserpine. Anal NY Acad. Li. 61,92–100 (1955).
   PubMedGoogle Scholar
• Naidoo D. The effect of reserpine (Serpasil) on the chronic disturbed schizophrenic: A comparative study of rauwolfia alkaloids and electroconvulsive therapy. J. Nerv. Mental Dir. 123,1–13 (1956).
   PubMedGoogle Scholar
• Gore CP, Egan GP, Walton D. The place of reserpine in the treatment of the chronic psychotic patient. Am. J. Psych. 114,333–337 (1957).
   Google Scholar
• Bacher NM, Lewis HA. Addition of reserpine to antipsychotic medication in refractory chronic schizophrenic outpatients. Am. J. Psych. 132,12 (1975).
   Google Scholar
• Berlant JL. Neuroleptics and reserpine in refractory psychosis. J. Clin. PTchopharmacol 6,180–184 (1986).
   PubMed Web of Science ®Google Scholar
• Christinson GW, Kirsch DG, Wyatt RJ. When symptoms persist: choosing among alternative somatic treatments for schizophrenia. Schiz. Bull. 17, 217–245 (1991).
   Google Scholar
• •Review of polypharmacology. Critically reviews the use of various agents as augmentation or supplemental therapy in schizophrenia.
   Google Scholar
• Tuteur W, Lepson D. Combined reserpine-chlorpromazine therapy in highly disturbed psychotics. In: 7ionquilizing Drug American Association for the Advancement of Science, Washington DC, USA (1957).
   Google Scholar
• Wassef AA, Watson DJ, Morrison P, Bryand S, Flack J. Neuroleptic valproic acid combination in treatment of psychotic symptoms. A three case report. J. Clin. PTchopharmacol 9,45–48 (1989).
   Google Scholar
• Wassef AA, Hafiz NG, Hampton D, Molloy M. Divalproex sodium augmentation of haloperidol in hospitalized patients with schizophrenia: clinical and economic implications. J. Clin. Psychopharmacol. 21,21–26 (2001).
   PubMed Web of Science ®Google Scholar
• Gundurewa V, Beckmann H, Zimmer R, Ruther E Effect of valproic acid on schizophrenic syndromes. Arzneimittel-Forschung30, 1212–1213 (1980).
   Web of Science ®Google Scholar
• Ko GN, Korpi ER, Freed WJ, Zalcman SJ, Bigelow LB. Effect of valproic acid on behavior and plasma amino acid concentrations in chronic schizophrenic patients. Bid Psych. 20,199–228 (1985).
   Google Scholar
• Lautin A, Angrist B, Gershon S, Heckl K, Karobath M. Sodium valproate in schizophrenia: some biochemical correlates. BE J. Psych. 137,240-244 (1980).
   Google Scholar
• Linnoila M, Viukari M, Hietala O. Effect of sodium valproate on tardive dyskinesia. Br. Psych. 129,114–119 (1976).
   Google Scholar
• Casey DE, Daniel DG, Wassef AA, Tracy KA, Wozniak P, Sommerville KW Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia. Neuropsychopharmacology28, 182–192 (2003).
   PubMed Web of Science ®Google Scholar
• Delva MJ, Letemendia FJP. Lithium treatment in schizophrenia and schizoaffective disorders. BE J. Psych. 144, 387–400 (1982).
   Google Scholar
• Lemer Y, Mintzer Y, Schastatzky M. Lithium combined with haloperidol in schizophrenic patients. BE J. Psych. 153, 359–362 (1988).
   PubMedGoogle Scholar
• Zemlan FP, Hirschowitz J, Sautter FJ Garver DL. Impact of lithium therapy on core psychotic symptoms of schizophrenia. BE J. Psych. 144,64–69 (1984).
   Google Scholar
• Martin JC, Palenciano G, Perez R The effectiveness of combining lithium with olanzapine in the treatment of resistant schizophrenia. J Clin. Psych. 61,948 (2000).
   Google Scholar
• Collins PJ, Larkin EP, Subsets APW Lithium carbonate in chronic schizophrenia — a brief trial of lithium carbonate added neuroleptics for treatment of resistant schizophrenic patients. Acta Psych. Scam 84,150–154 (1991).
   PubMed Web of Science ®Google Scholar
• Expert Consensus Guideline Series: treatment of schizophrenia. J. Clin. Psych. 57(Suppl. 12B), 1–58 (1996).
   Google Scholar
• Singh AN, Saxena, Nelson HL A controlled trial of trazodone in chronic schizophrenic patients with pronounced depressive symptomatology. Curr: Ther. Res. 23,485–501 (1978).
   Google Scholar
• Sins SG, Morgan V, Fagerstrom R, Rifkin A, Cooper TB. Adjunctive imipramine in the treatment of post-psychotic depression. AIM Gen. Psych. 42,533–539 (1987).
   Google Scholar
• Becker RE. Implications of the efficacy of thiothixene and a chlorpromazine-imipramine combination for depression in schizophrenia. Am. J. Psych. 140,208–211 (1983).
   PubMed Web of Science ®Google Scholar
• Donaldson SR, Gelenberg AJ, Baldassarini RJ. The pharmacologic treatment of schizophrenia — a progress report. Schiz. Bull. 11,5–28 (1985).
   Google Scholar
• Silver H. Fluvoxamine as an adjunctive agent in schizophrenia. CNS Drug Rev 7, 283–304 (2001).
   PubMedGoogle Scholar
• Silver H, Kushnir M, Kaplan A. Fluvoxamine augmentation in Clozapine resistant schizophrenia an open pilot study. Bid Psych. 40,671–674 (1996).
   Google Scholar
• Goff DC, Brotman AW, Waites M, McCormick S. Trial of fluoxetine added to neuroleptics for treatment-resistant schizophrenia patients. Am. J. Psych. 147, 492–494 (1990).
   PubMed Web of Science ®Google Scholar
• Muller-Siecheneder F, Muller MJ,llert A, Szegedi A, Wetzel H, Benkert O. Risperidone versus haloperidol and amitriptyline in the treatment of patients with a combined psychotic and depressive syndrome. J Gun. Fiychopharmacol 18, 111–120 (1998).
   Google Scholar
• Shelton RC, Tollefson GD, Tohen M eta]. A novel augmentation strategy for treating resistant major depression. Aim J Psych. 158, 131–134 (2001).
   Google Scholar
• Schulz SC, Kahn EM Baker RW eta]. Lithium and carbamazepine augmentation in treatment-refractory schizophrenia. In The Neuroleptic Nonresponsive Patient: CharacterizatMn and Treatment. Angrsit B, Schulz SC (Eds). American Psychiatric Press, Arlington, VA, USA 109–136 (1990).
   Google Scholar
• Wetterling T. Open clinical trial of carbamazepine in chronic schizophrenic in-patients. Pharmacopsychiatry20, 127–130 (1987).
   PubMedGoogle Scholar
• Carpenter WE Jr, Kurz R, Kirpatrick HB, Hanlon TE, Summerfelt AT, Buchanan RW Carbamazepine maintenance treatment in outpatient schizophrenics. Arch. Gen. Psych. 46, 69–72 (1991).
   Google Scholar
• Sramek, J. Herrera J, Costa J, Heh C, Tran-Johnson T, Simpson G. Carbamazepine trial in chronic refractory schizophrenia. Am.j Fiych. 145, 748–750 (1988).
   Google Scholar
• Hakola HPA Laulumma VA. Carbamazepine in treatment of violent schizophrenia. Lancet 1, 1358 (1982).
   Google Scholar
• Luchins D. Carbamazepine for the violent psychiatric patient. Lancet 1, 766 (1983).
   PubMed Web of Science ®Google Scholar
• Mendoza R, Djenderdjian A, Adams J, Ananth J. Midazolam in acute psychotic patients with hyperarousal. J Gun. Psych. 48, 291–292 (1987).
   Google Scholar
• Pilowski LS, Ring H, Shine PJ, Battersby M, Lader M. Rapid tranquillization. A survey of emergency prescribing in a general hospital. BE J. Psych. 160, 831–835 (1992).
   Google Scholar
• Wolkowitz OM, Breier A, Doran AR Alprazolam augmentation of the antipsychotic effects of fluphenazine in schizophrenic patients Arch. Gen. Psych. 45, 664–671 (1988).
   PubMed Web of Science ®Google Scholar
• Herrera JM, Alvarez WA, Frienhar JP, Lawson WB, Sramek JJ. Adjunctive clonazepam in the treatment of chronic schizophrenia. Int. J. Psychosomatics38, 17–20 (1991).
   PubMedGoogle Scholar
• Wolkowitz OM, Brier A, Doran A etal Benzodiazapines in the treatment of schizophrenia: a review and reappraisal. Am. J. Psych. 148, 714–726 (1991).
   PubMed Web of Science ®Google Scholar
• Geagea K, Ananth J. Response of a psychiatric patient to vitamin B12 therapy. Dis. Nerv. Syst. 36, 343–344, (1975)
   Google Scholar
• Petrie WM, Ban TA, Ananth JV. The use of nicotinic acid and pyridoxine in the treatment of schizophrenia. Int. Pharmacopsychiatry16, 245–250 (1981).
   Google Scholar
• Wahlbeck K, Cheine MV, Gilbody S, Ahonen J. Efficacy of P-blocker supplementation for schizophrenia: a systematic review of randomized trials. Schiz. Res. 41, 341–347 (2000).
   PubMedGoogle Scholar
• Bacher NM, Sanzone MM, Kaup B. Cyproheptadine in the treatment of resistant chronic schizophrenics with prior negative response to fluoxetine. Psychopharmacol 14, 474–475 (1994).
   Google Scholar
• Wolf MA, Diener JM, Lajeunesse C, Shriqui CL. Low-dose bromocriptine in neuroleptic-resistant schizophrenia: a pilot study. Biol. Psych. 31, 1166–1168 (1992).
   PubMedGoogle Scholar
• Litman RE, Su TP, Potter WZ Hong WW, Pickar D. Idazoxan and response to typical neuroleptics in treatment-resistant schizophrenia. Comparison with the atypical neuroleptic, clozapine. BE J. Psych. 168, 571–579 (1996).
   Google Scholar
• Crow TJ. The two-syndrome concept: origins and current status. Schiz. Bull. 11, 471–486 (1985).
   PubMed Web of Science ®Google Scholar
• Tollefson G, Sanger TM. Negative symptoms: a path analytic approach to a double-blind, placebo and haloperidol controlled clinical trial with olanzapine. Am. J. Psych. 154, 466–474 (1997).
   PubMed Web of Science ®Google Scholar
• Kopelowicz A, Zarate, R, Tripodis K, Gonalez V, Mintz J. Differential efficacy of olanzapine for deficit and nondeficit negative symptoms in schizophrenia. Am. J. Psych. 157, 987–993, (2000).
   PubMed Web of Science ®Google Scholar
• Buchanan FH, Patron RV, Warren JW, Baker EP. Double-blind trial of L-dopa in chronic schizophrenia. Aust. NZ J. Psych. 9, 269–271(1975).
   PubMed Web of Science ®Google Scholar
• Gerlach J, Luhdorf K. The effect ofl-dopa on young patients with schizophrenia, treated with neuroleptic drugs. A double-blind cross over trial with Madopar and placebo. PTchopharmacologla 44, 105–110 (1975).
   Google Scholar
• Inanaga K, Nakazawa Y, Inouye K, Tachibana H, Oshima M. Double-blind controlled study ofl-dopa therapy in schizophrenia. Folia Psych. Nemo'. Jpn 29, 149–167 (1975).
   Google Scholar
• Evins AE, Goff DC. Adjunctive antidepressant drug therapies in the treatment of negative symptoms of schizophrenia. CNS Drugs 6, 130–147 (1996).
   Google Scholar
• Adan F, Sins SG. Trials of adjunctive alprazolam in 'negative symptom' patients. Cn.J Psych. 34, 326–328 (1989).
   Google Scholar
• Cernansky JG, Lombrozo L, Gulevich GO, Hollister LE. Treatment of negative schizophrenic symptoms with alprazolam. A preliminary open label study. J. Clin. Psychopharmacol 4, 349–352 (1984).
   PubMedGoogle Scholar
• Bermanzohn PC, Sins SG. Akinesia: a syndrome common to Parkinsonism, retarded depression and negative symptoms. Comp. Psych. 33,221–232 (1992).
   PubMed Web of Science ®Google Scholar
• Carpenter WT Jr, Heinrichs DW, Alphs LD. Treatment of negative symptoms. Schiz. Bull. 11, 440–452 (1985).
   Google Scholar
• Tandon R, Mann N, Eisner W, Coppard N. Effect of anticholinergic medication on positive and negative symptoms in medication free schizophrenic patients. Psych. Res. 31, 235–241 (1990).
   PubMed Web of Science ®Google Scholar
• Evins AF, Amico E, Posever TA, Toker R, Goff DC. D-cydoserine added to risperidone in patients with primary negative symptoms. Schiz. Res. 56, 19–23 (2002).
   Google Scholar
• Evins AE, Fitzgerald SM, Wine L, Rosselli R, Goff DC. Placebo-controlled trial of glycine added to clozapine in schizophrenia. Am. J. Psych. 157, 826–828 (2000).
   Google Scholar
• Heresco-Levy U, Errnilov M, Shimoni J, Shapira B, Silipo G, Javitt DC. Placebo-controlled trail of D-cylcoserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia. Am. J. Psych. 159, 480–482 (2002).
   Google Scholar
• Javic DC. Management of negative symptoms of schizophrenia. Curl: Psych. Rep. 3, 413–417 (2001).
   Google Scholar
• •Review of polypharrnacology. Critically reviews the use of various agents as augmentation or supplemental therapy in schizophrenia.
   Google Scholar
• Rosse RB, Deutsch SI. Adjuvant galantamine administration improves negative symptoms in a patient with treatment-refractory schizophrenia. Neuropharmacol 25, 272–275 (2002).
   Google Scholar
• National Institute for clinical excellence: Schizophrenia. Core interventions in the treatment and management of schizophrenia in primary and secondary care. National Institute of Clinical Excellence (NICE) London, UK. (2002). Affiliations
   Google Scholar